Mycophenolate mofetil in liver transplantation: A review

Annals of Transplantation

Volumn 18, Issue 1, 2013, Pages 685-696

  Kaltenborn, Alexander ^a,b   Schrem, Harald ^b  

^a Federal Armed Forces Medical Center Hannover   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cellcept; de novo malignancy; Enteric coated mycophenolate; Mycophenolic acid; Myfortic; Solid organ transplantation

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN A; GANCICLOVIR; INOSINATE DEHYDROGENASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANTOPRAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTON PUMP INHIBITOR; STEROID; TACROLIMUS; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL PAIN; ANEMIA; ANTIMICROBIAL ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CHOLESTASIS; CLINICAL PRACTICE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; ENTERIC COATED TABLET; GASTRITIS; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LEUKOPENIA; LIVER TRANSPLANTATION; LOW DRUG DOSE; META ANALYSIS (TOPIC); MYOPATHY; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PNEUMONIA; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; VOMITING;

END STAGE LIVER DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 84891595240     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.889299     Document Type: Review

References (98)

1. Gosio B: Ricerche batteriologiche e chimiche sulle alterazioni del mais. Contributo all'etiologia della pellagra. Rivista d'Igiene e Sanità Pubblica. Ed. 7, No. 21, 1896; 484-87; No. 22, 869-88
2. Williams RH, Lively DH, DeLong DC et al: Mycophenolic acid: antiviral and antitumor properties., J Antibiot (Tokyo), 1968; 21: 463-64
3. Sweeney MJ, Gerzon K, Harris PN et al: Experimental antitumor activity and preclinical toxicology of mycophenolic acid. Cancer Res, 1972; 32: 1795-802
4. Sweeney MJ, Hoffman DH, Esterman MA: Metabolism and biochemistry of mycophenolic acid. Cancer Res, 1972; 32: 1803-9
5. Tressler RJ, Garvin LJ, Slate DL: Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer, 1994; 57: 568-73
6. Leckel K, Beecken WD, Jonas D et al: The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells. Clin Exp Immunol, 2003; 134: 238-45
7. Blaheta RA, Leckel K, Wittig B et al: Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc, 1999; 31: 1250-52
8. Engl T, Makarević J, Relja B: Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer, 2005; 5: 4
9. Koehl GE, Wagner F, Stoeltzing O: Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability. Transplantation, 2007; 83: 607-14
10. Carr SF, Papp E, Wu JC, Natsumeda Y: Characterization of human type I and type II IMP dehydrogenases. J Biol Chem, 1993; 268: 27286-90
11. Birkeland SA: Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. Transplantation, 1998; 66: 1207-10
12. Kaltenborn A, Kurok M, Vogel A et al: Influence of immunosuppression on the development of de novo malignancies after liver transplantation. [Submitted]
13. O'Neill JO, Edwards LB, Taylor DO: Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant, 2006; 25: 1186-91
14. Allison AC, Hovi T, Watts RW, Webster AD: Immunological observations on patients with Lesch-Nyhan syndrome, and on the role of denovo purine synthesis in lymphocyte transformation. Lancet, 1975; 2: 1179-83
15. Franklin TJ, Cook JM: The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J, 1969; 113: 515-24
16. Lee WA, Gu L, Miksztal AR et al: Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res, 1990; 7: 161-66
17. Detry O, de Roover A, Delwaide J et al: The use of mycophenolate mofetil in liver transplant recipients. Expert Opin Pharmacother, 2003; 4: 1949-57
18. Lintrup J, Hyltoft-Petersen P, Knudtzon S, Nissen NI: Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep, 1972; 56: 229-35
19. Shaw LM, Korecka M, Venkataramanan R et al: Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant, 2003; 3: 534-42
20. Nowak I, Shaw LM: Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem, 1995; 41: 1011-17
21. van Gelder T: Mycophenolate blood level monitoring: recent progress. Am J Transplant, 2009; 9: 1495-99
22. Pescovitz MD, Conti D, Dunn J et al: Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant, 2000; 14: 179-88
23. Nashan B, Ivens K, Suwelack B et al: Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study. Transplant Proc, 2004; 36: 521S-523S
24. Pietruck F, Abbud-Filho M, Vathsala A et al: Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. Transplant Proc, 2007; 39: 103-8
25. Budde K, Glander P, Diekmann F et al: Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother, 2004; 5: 1333-45
26. Srinivas TR, Kaplan B, Meier-Kriesche HU: Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother, 2003; 4: 2325-45
27. Jain AB, Yee LD, Nalesnik MA et al: Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation, 1998; 66: 1193-200
28. Wiesner RH, Shorr JS, Steffen BJ et al: Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl, 2005; 11: 750-59
29. Boudjema K, Camus C, Saliba F et al: Reduceddose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant, 2011; 11: 965-76
30. Wiesner RH, Fung JJ: Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl, 2011; 17: S1-9
31. Lee PC, Chang SS, Shieh SC et al: Cyclosporine or tacrolimus: which is the better partner for myfortic or cellcept? Transplant Proc, 2012; 44: 137-39
32. CellCept package insert (2005), Nutley, NJ: Roche Laboratories
33. Chapman JR: Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant, 2011; 11: 693-97
34. Mihatsch MJ, Kyo M, Morozumi K et al: The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol, 1998; 49: 356-63
35. Textor SC, Taler SJ, Canzanello VJ et al: Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl, 2000; 6: 521-30
36. McAlister VC, Haddad E, Renouf E et al: Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a metaanalysis. Am J Transplant, 2006; 6: 1578-85
37. Collett D, Mumford L, Banner NR et al: Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant, 2010; 10: 1889-96
38. Wiesner R, Rabkin J, Klintmalm G et al: A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl, 2001; 7: 442-50
39. Moore J, Middleton L, Cockwell P et al: Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis. Transplantation, 2009; 87: 591-605
40. Jain A, Kashyap R, Demetris AJ et al: A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl, 2002; 8: 40-46
41. Berlakovich G, Windhager T, Wamser P: Limits of MMF in liver transplantation-discontinuation of CyA withdrawal trial [abstract] Second joint AST/ASTS meeting 2001
42. Pageaux GP, Rostaing L, Calmus Y et al: Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl, 2006; 12: 1755-60
43. Schlitt HJ, Barkmann A, Böker KH et al: Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet, 2001; 357: 587-91
44. Schmeding M, Kiessling A, Neuhaus R et al: Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial. Transplantation, 2011; 92: 923-29
45. Stewart SF, Hudson M, Talbot D et al: Mycophenolate mofetil monotherapy in liver transplantation. Lancet, 2001; 357: 609-10
46. Neuberger JM, Mamelok RD, Neuhaus P et al: Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant, 2009; 9: 327-36
47. Kriss M, Sotil EU, Abecassis M et al: Mycophenolate mofetil monotherapy in liver transplant recipients. Clin Transplant, 2011; 25: E639-46
48. Shipkova M, Armstrong VW, Oellerich M, Wieland E: Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol, 2005; 1: 505-26
49. Oellerich M, Shipkova M, Schütz E et al: Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit, 2000; 22: 20-26
50. van Gelder T, Klupp J, Barten MJ et al: Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit, 2001; 23: 119-28
51. van Gelder T, Hilbrands LB, Vanrenterghem Y et al: A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation, 1999; 68: 261-66
52. Weber LT, Shipkova M, Armstrong VW et al: The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. Am Soc Nephrol, 2002; 13: 759-68
53. Heller T, van Gelder T, Budde K et al: Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. Am J Transplant, 2007; 7: 1822-31
54. van Gelder T, Silva HT, de Fijter JW et al: Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation, 2008; 86: 1043-51
55. Le Meur Y, Büchler M, Thierry A et al: Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant, 2007; 7: 2496-503
56. Behrend M: Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf, 2001; 24: 645-63
57. Pourfarziani V, Panahi Y, Assari S et al: Changing treatment protocol from azathioprine to mycophenolate mofetil: decrease in renal dysfunction, increase in infections. Transplant Proc, 2007; 39: 1237-40
58. ter Meulen CG, Wetzels JF, Hilbrands LB: The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant, 2000; 15: 711-14
59. Ritter ML, Pirofski L: Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis, 2009; 11: 290-97
60. Neyts J, Andrei G, De Clercq E: The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother, 1998; 42: 216-22
61. [No authors listed] Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet, 1995; 345: 1321-25
62. [No authors listed] A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation, 1996; 61: 1029-37
63. Pérgola PE, Kancharla A, Riley DJ: Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. Transplantation, 2001; 71: 994-97
64. Armenti VT, Radomski JS, Moritz MJ et al: Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl, 2005: 69-83
65. Schoner K, Steinhard J, Figiel J, Rehder H: Severe facial clefts in acrofacial dysostosis: a consequence of prenatal exposure to mycophenolate mofetil? Obstet Gynecol, 2008; 111: 483-86
66. Anderka MT, Lin AE, Abuelo DN et al: Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A, 2009; 149A: 1241-48
67. McKay DB, Josephson MA: Pregnancy in recipients of solid organs-effects on mother and child. N Engl J Med, 2006; 354: 1281-93
68. Tendron A, Gouyon JB, Decramer S: In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol, 2002; 17: 121-30
69. Detry O, de Roover A, Delwaide J et al: The use of mycophenolate mofetil in liver transplant recipients. Expert Opin Pharmacother, 2003; 4: 1949-57
70. Shrestha NK, Mossad SB, Braun W: Pneumonitis associated with the use of mycophenolate mofetil. Transplantation, 2003; 75: 1762
71. Galindo M, Cabello A, Joven B et al: Mycophenolate mofetil induced myopathy in a patient with lupus nephritis. J Rheumatol, 2005; 32: 188-90
72. Takhampunya R, Ubol S, Houng HS et al: Inhibition of dengue virus replication by mycophenolic acid and ribavirin. J Gen Virol, 2006; 87: 1947-52
73. Wu J, Xie HY, Jiang GP et al: The effect of mycophenolate acid on hepatitis B virus replication in vitro. Hepatobiliary Pancreat Dis Int, 2003; 2: 410-13
74. Henry SD, Metselaar HJ, Lonsdale RC et al: Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology, 2006; 131: 1452-62
75. Husain S, Singh N: The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. Clin Infect Dis, 2002; 35: 53-61
76. Padalko E, Verbeken E, Matthys P et al: Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol, 2003; 3: 25
77. Morrey JD, Smee DF, Sidwell RW, Tseng C: Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res, 2002; 55: 107-16
78. Neyts J, Meerbach A, McKenna P, De Clercq E: Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res, 1996; 30: 125-32
79. Li H, Tanaka K, Chhabra A et al: Vascular remodeling 1 year after cardiac transplantation. J Heart Lung Transplant, 2007; 26: 56-62
80. Kobashigawa JA, Tobis JM, Mentzer RM et al: Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant, 2006; 6: 993-97
81. Romero F, Rodríguez-Iturbe B, Pons H et al: Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis, 2000; 152: 127-33
82. Zucker K, Tsaroucha A, Olson L et al: Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit, 1999; 21: 35-43
83. Cooper M, Salvadori M, Budde K et al: Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. Transplant Rev, 2012; 26: 233-40
84. Rupprecht K, Schmidt C, Raspé A et al: Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol, 2009; 49: 1196-201
85. Miura M, Satoh S, Inoue K et al: Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit, 2008; 30: 46-51
86. Kofler S, Deutsch MA, Bigdeli AK et al: Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant, 2009; 28: 605-11
87. Benlloch S, Berenguer M, Prieto M et al: De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transpl, 2004; 4: 596-604
88. Kauffman HM, Cherikh WS, Cheng Y et al: Maintenance immunosuppression with targetof-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation, 2005; 80: 883-89
89. Finkenstedt A, Graziadei IW, Oberaigner W et al: Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant, 2009; 9: 2355-61
90. Sapisochin G, Bilbao I, Dopazo C et al: Evolution and management of de novo neoplasm postliver transplantation: a 20-year experience from a single European centre. Hepatol Int, 2011; 5: 707-15
91. Yokoyama I, Hayashi S, Kobayashi T et al: Immunosuppressive drugs and their effect on experimental tumor growth. Transpl Int, 1995; 8: 251-55
92. Chen L, Pankiewicz KW: Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel, 2007; 10: 403-12
93. Guidicelli G, Chaigne-Delalande B, Dilhuydy MS et al: The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells. PLoS One, 2009; 4: e5493
94. Zheng ZH, Yang Y, Lu XH et al: Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARg. Eur J Pharmacol, 2011; 658: 1-8
95. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 2000; 47: 85-118
96. Robson R, Cecka JM, Opelz G et al: Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant, 2005; 5: 2954-60
97. Cherikh WS, Kauffman HM, McBride MA et al: Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation, 2003; 76: 1289-93
98. Look M, Stern E, Quin AW et al: Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice. J Clin Invest, 2013; 123: 1741-49